
    
      Participants in this study will be randomly assigned to receive either 2.5 mg or 10 mg of
      vortioxetine or a placebo once daily for an eight week treatment period.

      Participants will be seen weekly during the first 2 weeks of treatment, and then every 2
      weeks up to the end of the 8-week treatment period. Total commitment time is up to 12 weeks.
    
  